This study explored the hypotheses that post-NAC plasma circulating tumor DNA (ctDNA) fraction (TF) reflect pathologic response as continuum measured by the residual cancer burden (RCB) score. ctDNA was assessed using the PredicineBEACON™ assay, in 3 mL archived plasma isolated from EDTA tubes collected post-NAC but before surgery from 44 patients with stage I/III triple negative breast cancer (TNBC) who received durvalumab and weekly nab-paclitaxel followed by doxorubicin/cyclophosphamide on a clinical trial (NCT02489448). Circulating free tumor DNA methylation profiling was performed using PredicineEPIC™ assay in paired pre- and post-NAC plasma (N=30).

September 2024

In collaboration with Yale Cancer Center

In this study,  AR status was assessed at baseline utilizing the PredicineCARE™ cell-free DNA targeted panel. ctDNA tumor fraction of 0.005 was used to define detectability as per the limit of detection guidelines from Predicine.

September 2024

In collaboration with Bristol Myers Squibb

In this study,  PredicineWES+™ was utilized to explore the prognostic significance of ILRH on paired positron emission tomography/computed tomography (PET/CT) in the context of abiraterone therapy.

August 2024

In collaboration with Fudan University Shanghai Cancer Center

In a single-arm investigator initiated clinical trial for patients with untreated advanced HER2+
gastroesophageal adenocarcinoma, bevacizumab was added to standard of care capecitabine, oxaliplatin, and trastuzumab in 36 patients. The MRD status of mutations identified at time of resistance were tracked on PredicineCARE™ using PredicineCARE™ Ultra. To analyze this data we leveraged the workflow from PredicineBEACON, a personalized MRD assay that tracks up to 50 personalized mutations plus 500 hot spot mutations.

August 2024

In collaboration with Dana Farber Cancer Institute

In the Phase II FIGHT-207 trial, PredicineCARE™ played a crucial role in evaluating pemigatinib in patients with advanced FGFR-altered solid tumors. The trial results were impressive, demonstrating significant responses across multiple tumor types, with a notable 26.5% response rate in patients with FGFR1-3 fusions, including glioblastoma and pancreatic cancers-tumor types not previously known to respond to FGFR inhibitors.

May 2024

In this study, eight commercial assays measuring baseline ctDNA were blinded and included in the
analysis (labeled Cohort A-I). Five assays (62.5%) were tumor-informed (i.e., mutations
identified in the primary tumor tissue that are tracked in the plasma), and three (37.5%)
were tumor-naïve (i.e., mutations were detected de novo from the plasma).

April 2024

In this research study, PredicineCARE™ (Assay G) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to eight other leading commercial liquid biopsy assays in China.

February 2024

The ctDNA variant allele frequency (VAF) detected by the PredicineCARE™ liquid biopsy next-generation sequencing assay, is highly correlated with clinical outcome and play a prognostic factor for patients with advanced breast cancer.

January 2024

Both PredicineCARE™ and PredicineHEME™ were used to identify baseline and resistance genetic alterations to the BTK inhibitors in patients in the phase 3 ASPEN study (NCT03053440) for Waldenström Macroglobulinemia (WM). The study identified that WM patients with CXCR4MUT or TP53MUT had worse prognosis compared to patients with WT alleles and zanubrutinib led to better clinical outcomes.

February 2024

This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech’s Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC). In this study, PredicineBEACON™ showcased remarkable biomarker results and played an important role in evaluating treatment efficacy and identifying drug resistance mechanisms at the MRD level.

December 2023

PredicineCARE™ generated exciting data and demonstrated novel use of circulating tumor DNA (ctDNA) to identify high risk, localized upper tract urothelial carcinoma (UTUC). This research underscores the immense potential of PredicineCARE™ ctDNA platform, demonstrating ctDNA as a highly predictable and strong prognostic biomarker for selecting patients for neoadjuvant chemotherapy.

October 2023

This Genentech sponsored study demonstrated the clinical utility of blood-informed PredicineBEACON™ MRD ctDNA and PredicineWES+™ assays for target engagement, therapy monitoring, and resistance mechanism study in NSCLC, colorectal cancer, and other cancers.

August 2023

In this new study, PredicineATLAS™ was used to assess the predictive utility of longitudinal circulating tumor DNA (ctDNA) analysis from a single-institution biomarker cohort.

August 2023

PredicineATLAS™ was used to assess the ability of cell-free urinary and plasma tumor DNA (cfDNA) to predict pathologic stage at radical cystectomy for patients with clinical muscle-invasive bladder cancer.

August 2023

In this research study, PredicineCARE™  was used to for targeted sequencing on 407 plasma samples from 375 men with mCRPC.

August 2023

Using PredicineCARE™  to perform comprehensive genomic profiling on DNA extracted from formalin-fixed, paraffin-embedded samples.

June 2023

In this research study, PredicineWES™  boosted whole exome sequencing was used to analyze circulating tumor DNA (ctDNA) to identify genomic features for predicting and monitoring treatment resistance.

January 2023

PredicineATLAS™  liquid biopsy next-generation sequencing assay was used to compare gemcitabine and nab-paclitaxel with and without immune checkpoint inhibitors durvalumab and tremelimumab in 180 patients with mPDAC. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and objective response rate.

August 2022

In this research study, PredicineATLAS™ (Assay B) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to four other leading commercial liquid biopsy assays.

May 2022

The PredicineATLAS™ panel was used to detect germline variants in Chinese patients with advanced breast cancer.

April 2022

In this study, PredicineCARE™ is used to evaluate circulating tumor DNA (ctDNA) in blood or urine, which can be used as biomarkers of PCa and the combination of these markers may increase the sensitivity and specificity of the detection of PCa.

March 2022

In this study, PredicineCARE™ is used to perform a retrospective analysis of serially profiled cell-free DNA (cfDNA) alterations in blood samples collected from mCRPC patients before and after starting chemotherapy who were followed for response and clinical outcomes.

March 2022

Predicine’s cfDNA and cfRNA assays were utilized to assess the role of somatic alterations on treatment resistance in patients with metastatic castration-resistant prostate cancer.

October 2021

Utilizing the PredicineCARE™ assay, this study demonstrates that urinary tumor DNA (utDNA) outperformed circulating tumor DNA (ctDNA) from blood samples in identifying somatic alterations in patients with newly diagnosed urothelial bladder cancer.

September 2021

In a study, the PredicineCARE™ and PredicineRNA™ liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.

September 2021

The PredicineCARE™ liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.

August 2021

Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.

April 2021

PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.

April 2021

Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification. 

November 2020

The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.

May 2020

Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.

April 2020

Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.

February 2020

The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.

December 2019

February 2023

February 2023

February 2023

Nathan Standifer, PhD; Yonchu Jenkins; Sam  H. Whiting, MD, PhD; Thomas  W. Dubensky, Jr., PhD; 

November 2022

Jingyu Zhang, Ruiyun Zhang, Feng Xie, Yue Zhang, Pan Du, Shidong Jia, Haige Chen, Guanglei Zhuang

September 2022

Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Shana Thomas, Lindsay Peterson, Xiaohong Wang, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma

September 2022

Sen Yang, Haoran Tang, Feng Xie, Yue Zhang, Shidong Jia, Qiming Wang

September 2022

Heather L Huelster, Elizabeth A. Green, Alex C. Soupir, Kyle M. Rose, Esther N. Katende, Shreyas U Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Alice Yu, Philippe E. Spiess, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li

May 2022

Heather Huelster, Elizabeth A. Green, Alex C. Soupir, Esther N. Katende, Kyle M. Rose, Shreyas U. Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Philippe E. Spiess, Alice Yu, Youngchul Kim, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li

February 2022

Heidi Fettke, Christine Hauser, Edmond Kwan, Chao Dai, Tiantian Zheng, Amy Wang, Winston Tan, Pan Du, Nicole Ng, Patricia Bukczynska, Siavash Foroughi, Lisa-Jane K. Graham, Lisa Horvath, Kate Lynette Mahon, Shidong Jia, Manish Kohli, Arun Azad

February 2022

Ruiyun Zhang, Jingyu Zang, Feng Xie, Yue Zhang, Akezhouli Shahatiaili, Yiqiu Wang, Pan Du, Shidong Jia, Guanglei Zhuang, Yiran Huang, Haige Chen

February 2022

Feng Xie, Jingyu Zang, Yue Zhang, Ruiyun Zhang, Yong Huang, Guanglei Zhuang, Haige Chen, Pan Du, Shidong Jia

February 2022

Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli

December 2019

Pan Du, Eric Jia and Zhixin Zhao

December 2019

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee

June 2019

Jianjun Yu, Jianguo Dong, Amy Wang, Joseph S. Krueger

April 2019

Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du

April 2019

Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu

February 2019